This study was designed to test, in a direct comparison, the claim that indapamide has fewer adverse effects than HCTZ on lipids. The ratio of TC to HDL was chosen as the main focus because in the Framingham study it was a stronger predictor of risk than any of the individual lipid levels . Effects on individual lipids, blood pressure, heart rate, blood glucose and electrolytes, as well as routine safety blood tests, were also recorded.
In this double-blind, randomized, double dummy parallel group trial, patients were allocated to six months of treatment with indapamide 2.5 mg/day or HCTZ 25 mg/day. Randomization occurred after a one-month washout period. ventolin inhaler
These doses were chosen because at the time they were common doses of the two drugs that were thought to be equivalent with respect to blood pressure lowering effects. The doses were also in the low end of the range for HCTZ compared with historically higher doses that had more pronounced metabolic effects, but were high enough that some metabolic effect was expected.
The study was initiated at the Hypertension Research Unit at Victoria Hospital, London, Ontario and was finished (after a hospital merger and move of the research unit and personnel) at the Stroke Prevention and Atherosclerosis Research Centre of the Robarts Research Institute, London, Ontario.
Forty-four patients with mild to moderate hypertension were recruited from the Atherosclerosis Prevention Clinic after expressing interest in participating in research on a routine questionnaire given to all new patients at the clinic.